Addyi Pharmacokinetics (ADME): How Flibanserin Is Absorbed, Metabolized, and Eliminated

Mechanism of Action: Serotonin-Dopamine Rebalancing

Flibanserin acts as a 5-HT1A receptor agonist and a 5-HT2A receptor antagonist in the prefrontal cortex, with secondary effects on dopaminergic pathways 1. This dual serotonergic activity reduces the tonic inhibition of sexual desire circuits while promoting dopamine and norepinephrine release in cortical regions implicated in motivation and reward.

The drug does not function as a hormonal agent. Unlike testosterone-based interventions for low desire, flibanserin modulates neurotransmitter balance in circuits governing sexual motivation [2](https://pubmed.ncbi.nlm.nih.gov/26## 578587/). Preclinical microdialysis studies in rats demonstrated that flibanserin increases dopamine and norepinephrine concentrations in the prefrontal cortex by 29% and 21%, respectively, while simultaneously decreasing serotonin levels by approximately 14% 3.

This neurochemical signature distinguishes flibanserin from SSRIs (which suppress desire) and from phosphodiesterase-5 inhibitors (which act peripherally). The BEGONIA trial (N=1,087) confirmed that flibanserin 100 mg at bedtime produced statistically significant improvements in desire scores measured by the Female Sexual Function Index, with a mean increase of 0.7 points over placebo across 24 weeks 4.

Absorption: Rapid Uptake With Significant First-Pass Loss

Flibanserin is rapidly absorbed from the gastrointestinal tract following oral administration. Per the FDA-approved prescribing information, the median time to maximum plasma concentration (Tmax) is approximately 0.75 hours under fasted conditions, with peak concentrations (Cmax) averaging 149 ng/mL after a single 100 mg dose 5.

Absolute bioavailability stands at 33%. This means two-thirds of the administered dose is lost before reaching systemic circulation, primarily through extensive first-pass hepatic extraction 5. The AUC at steady state is approximately 1 to 543 ng·h/mL with once-daily 100 mg dosing.

Food substantially alters the absorption profile. A high-fat meal increases Cmax by 56% and delays Tmax from 0.75 to 1.75 hours without significantly changing overall AUC 5. Because higher peak concentrations intensify sedation and hypotension, bedtime dosing on an empty stomach or after a light evening meal is the recommended administration strategy. The prescribing information explicitly warns against taking flibanserin during waking hours 6.

Distribution: Extensive Tissue Penetration

Flibanserin distributes extensively into tissues. The apparent volume of distribution (Vd/F) at steady state is approximately 1,187 L, indicating partitioning far beyond the plasma compartment 5. This large Vd is consistent with the drug's high lipophilicity (logP 3.7) and its target engagement in CNS tissues.

Plasma protein binding is approximately 98%, primarily to albumin and alpha-1-acid glycoprotein 5. Because only the unbound fraction crosses the blood-brain barrier to engage cortical serotonin receptors, conditions that alter protein binding (hepatic impairment, hypoalbuminemia) could theoretically increase CNS exposure.

Steady-state plasma concentrations are achieved within approximately 3 days of daily dosing, reflecting the 11-hour half-life and once-daily administration schedule. Accumulation ratio is modest at 1.5- to 2-fold relative to single-dose exposure 5.

Metabolism: CYP3A4-Dominant Biotransformation

The liver is the primary site of flibanserin clearance. CYP3A4 accounts for the majority of oxidative metabolism, with CYP2C19 serving as a secondary pathway 7. At least 35 metabolites have been identified in human plasma and excreta, none of which contribute meaningfully to pharmacologic activity at clinically observed concentrations.

The dominant metabolic reactions are N-dealkylation and hydroxylation. The major circulating metabolite (M1, a dealkylated species) reaches plasma concentrations approximately 60% of the parent compound but shows negligible affinity for 5-HT1A or 5-HT2A receptors 5.

CYP3A4 Inhibitor Interactions

This metabolic dependence on CYP3A4 creates the most clinically significant drug interaction associated with flibanserin. Coadministration with strong CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) increases flibanserin AUC by approximately 7-fold and Cmax by 4.5-fold 5. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, diltiazem, grapefruit juice) increase AUC by approximately 4.5-fold 8.

Both categories are contraindicated. The FDA mandated a Risk Evaluation and Mitigation Strategy (REMS) program specifically because these interactions precipitate severe hypotension and syncope 9. In the dedicated interaction study, subjects receiving flibanserin plus ketoconazole experienced mean systolic blood pressure decreases of 17 mmHg compared to flibanserin alone 5.

CYP2C19 Polymorphism Considerations

CYP2C19 poor metabolizers (approximately 2-5% of Caucasians and 13-23% of Asians) show flibanserin AUC increases of approximately 1.6-fold relative to extensive metabolizers 5. The FDA label does not require dose adjustment for CYP2C19 poor metabolizers, but clinicians should monitor for excess sedation in these patients. A pharmacogenomic analysis from 2016 confirmed that the AUC elevation in CYP2C19 poor metabolizers remains within a range that does not necessitate contraindication 10.

Elimination: Dual Renal and Fecal Excretion

Flibanserin is eliminated through both kidneys and the gastrointestinal tract after metabolic conversion. Following a single radiolabeled dose, 51% of radioactivity appeared in urine and 44% in feces 5. Less than 1% of the intact parent compound is excreted unchanged in urine, confirming that hepatic metabolism rather than renal filtration governs systemic clearance.

The terminal elimination half-life is approximately 11 hours following oral administration. Total body clearance (CL/F) is approximately 55 L/h 5. This half-life supports the once-daily bedtime dosing strategy and means that drug accumulation is minimal with consistent daily use.

Special Populations: Hepatic Impairment and Other Factors

Hepatic Impairment

Because CYP3A4-mediated first-pass metabolism determines bioavailability, liver dysfunction dramatically alters flibanserin exposure. Subjects with Child-Pugh B (moderate) cirrhosis showed a 4.5-fold increase in AUC compared to matched healthy controls 5. Flibanserin is contraindicated in any degree of hepatic impairment 11.

Renal Impairment

In subjects with severe renal impairment (eGFR <30 mL/min/1.73m²), no clinically meaningful change in flibanserin pharmacokinetics was observed 5. No dose adjustment is needed for any degree of renal impairment.

Age and Body Weight

Population pharmacokinetic modeling showed that age (range studied: 19-67 years) did not meaningfully alter flibanserin clearance 12. Body weight influenced volume of distribution as expected for a lipophilic compound, but exposure differences did not warrant weight-based dosing.

Alcohol Interaction: A Pharmacokinetic-Pharmacodynamic Concern

The flibanserin-alcohol interaction deserves separate pharmacokinetic discussion because it drove regulatory controversy. In a dedicated study, flibanserin 100 mg combined with 0.4 g/kg alcohol produced additive reductions in blood pressure (mean systolic drop of 12 mmHg) and increased somnolence without significantly altering flibanserin AUC or Cmax 13.

This indicates the interaction is pharmacodynamic (additive CNS depression) rather than pharmacokinetic in nature. The REMS program requires prescribers to counsel patients against alcohol use during flibanserin therapy 9. A 2018 post-marketing analysis found that real-world hypotension and syncope events occurred disproportionately in women who consumed alcohol within 2 hours of their flibanserin dose 14.

Clinical Pharmacokinetic Summary and Dosing Implications

The pharmacokinetic profile of flibanserin dictates several concrete prescribing decisions. The 33% bioavailability means that oral dose adjustments cannot compensate for CYP3A4 inhibitor coadministration; the magnitude of interaction (4.5- to 7-fold AUC increase) exceeds what dose reduction could safely manage 15. The 11-hour half-life supports bedtime-only administration: peak CNS effects coincide with sleep, while residual drug levels during waking hours are low enough to minimize daytime sedation.

For patients initiating flibanserin, the time to pharmacologic steady state (3 days) aligns with the clinical observation that therapeutic benefit typically requires 4-8 weeks of daily dosing, as receptor-mediated neuroplastic changes rather than acute drug levels drive efficacy 4. The BEGONIA and VIOLET trials both used 8-week minimum assessment windows for primary endpoints 16.

Prescribers should confirm CYP3A4 inhibitor status (including OTC supplements like goldenseal and grapefruit products), verify absence of hepatic disease, and document alcohol counseling per REMS requirements before writing the first prescription.